ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00752154
Previous Study | Return to List | Next Study

Curcumin in Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00752154
Recruitment Status : Unknown
Verified September 2008 by University of California, Los Angeles.
Recruitment status was:  Recruiting
First Posted : September 15, 2008
Last Update Posted : July 2, 2010
Sponsor:
Information provided by:
University of California, Los Angeles

September 11, 2008
September 15, 2008
July 2, 2010
January 2010
December 2010   (Final data collection date for primary outcome measure)
American College of Rheumatology 20% [ Time Frame: 4 month period ]
Proportion of pats achieving ACR 20 Response Criteria & Change in the circulating levels of markers of inflammation, immune activation, and acute-phase reactants, in cellular levels of expression of TNF-alpha, IL6, and COX-2, and transcription factors [ Time Frame: at the end of the study ]
Complete list of historical versions of study NCT00752154 on ClinicalTrials.gov Archive Site
  • Inflammatory cell signaling markers [ Time Frame: 4 month ]
  • Safety of curcumin [ Time Frame: 8 month ]
Not Provided
Not Provided
Not Provided
 
Curcumin in Rheumatoid Arthritis
Curcumin in Rheumatoid Arthritis - ACross-Over Pilot Study

Curcuma longa or turmeric is a tropical plant native to south and southeast tropical Asia. Perhaps the most active component in turmeric is curcumin which may make up 2-5% of the total spice in turmeric. The study drug being tested in this study is curcumin.

This study is called a cross-over study because all subjects will receive the study drug for a certain amount of time and then switch to placebo (an inactive substance) for a certain time or vice versa. The subject's participation may last up to 8 months.

The subject will be randomized (by chance; like flipping a coin) to receive either the study drug, curcumin, or placebo for 4 months. After 4 months, if the subject was taking curcumin they will stop taking it and begin to take placebo and if the subject was taking placebo they will stop taking it and begin taking curcumin for the remaining 4 months. By completion of the study, all 40 subjects will have taken curcumin and placebo for 4 months each.

Curcumin/placebo will be provided in capsule form and the subject will take it by mouth. The dose dose will be increased every week for up to a total of 4 grams per day.

Subjects will have blood tests, complete questionnaires, and be seen by the study doctor.

Not Provided
Interventional
Early Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Rheumatoid Arthritis
Drug: Curcumin (Longvida™)
Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Unknown status
40
20
January 2011
December 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Age ≥ 18 years; read and understand English
  2. Stable dose of non-steroidal anti-inflammatory agents (NSAID) for ≥ 2 weeks.
  3. Oral prednisone or equivalent ≤ 10 mg daily and stable dose for ≥ 2 weeks(and must be kept stable throughout the duration of the protocol).

    • ESR > 20 mm/hr, or CRP > 0.8 mg/dl
  4. May be using any of the following DMARDs: methotrexate, sulfasalazine, hydroxychloroquine or leflunomide. If using any of these DMARDs must be using them for ≥ 12 weeks and stable dose for ≥ 4 weeks. If using other DMARD, or DMARD combinations, these additional or other DMARDs must be stopped for ≥ 4 weeks before baseline visit. May also participate if patient not on DMARD,
  5. Subjects must be diagnosed with rheumatoid arthritis based on the revised American College of Rheumatology criteria:Presence of > swollen and > 6 tender joint count (28 joint count), and either ESR > 20 mm/hr or CRP > 0.8 mg/dl

Exclusion Criteria:

  1. Acute medical conditions deemed as inappropriate by the investigators (acute heart failure, uncontrolled diabetes mellitus, uncontrolled hypertension)
  2. AST/ALT > 1.5 upper limit of normal (ULN)
  3. Serum creatinine > 1.6 mg/dl
  4. Hemoglobin/Hematocrit < 10.0 gram/dl/ 30.0
  5. Platelet count < 100,000
  6. Current use of warfarin (as there is a drug interaction between curcumin and warfarin).
  7. Currently on biologic therapy (must have stopped etanercept for ≥ 4 weeks or adalimumab or infliximab for ≥ 8 weeks at time of Time 1 visit),
  8. Women who are pregnant,
  9. Subjects who are taking digoxin, warfarin and/or heparin,
  10. Subjects with a history of antiphospholipid syndrome and other thrombophilic states,
  11. Subjects who have an INR >= 1.5 at baseline,
  12. Subjects with acute episode(s) of cholecystitis within the last 6 months,
  13. Subjects with active peptic ulcer disease within the last 6 weeks
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00752154
07-12-051
No
Not Provided
Not Provided
Dinesh Khanna, M.D., MS - Principal Investigator, UCLA
University of California, Los Angeles
Not Provided
Principal Investigator: Dinesh Khanna, M.D. University of California, Los Angeles
University of California, Los Angeles
September 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP